News | October 28, 2008

Cardiac Biomarker Soluble ST2 Offers Value in the Care of Heart Failure Patients

October 29, 2008 - Critical Diagnostics today announced the publication of a research paper and an accompanying editorial comment further refining the clinical value and risk of mortality prediction power of the cardiac biomarker soluble ST2 (sST2).

The research paper, “Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients with Acute Heart Failure” and editorial comment “Serum Soluble ST2 as a Biochemical Marker of Acute Heart Failure” was published in the Journal of the American College of Cardiology, Oct. 28. The result of this latest study expands understanding of this biomarker in patients with acute destabilized heart failure (ADHF), further refining the clinical value of sST2 in these patients.

The study analyzed 346 patients diagnosed with ADHF derived from two previously reported prospective clinical trials of dyspneic emergency department patients. This study confirms previously reported results that sST2 powerfully predicts mortality, independent of established clinical and biochemical predictors in this setting. Senior author on this paper, Dr. James L. Januzzi, associate professor of medicine at Harvard Medical School, and physician in the division of cardiology at the Massachusetts General Hospital where he is also the chief of the coronary care unit, added, “What is interesting to us are the emerging data linking sST2 to a wide range of cardiovascular diseases, including coronary artery disease and heart failure. On a biological level ST2 appears to play a pivotal role in the complications stemming from both states, which raises the question of an entirely new avenue of exploration for cardiac therapeutics. Furthermore, the clinical value of sST2 measurement appears established - together with testing for conventional markers such as natriuretic peptides, sST2 adds clear, solid value for assessing risk; with this better ability to recognize risk will follow more opportunity for timely and correct intervention, and the hope to better reduce the potential for complications.”

Cardiovascular disease is the leading cause of death in the U.S. and the incidence of heart failure, as a form of cardiovascular disease, is increasing. The research described in this paper confirms that sST2 is a powerful and accurate biomarker for prediction of near term mortality in ADHF patients and its clinical use may lead to improvements in patient care.

For more information: www.criticaldiagnostics.com, www.jacc.org

Related Content

Alere point of care POC testing for INR
News | Point of Care Testing| July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
Siemens Xprecia Stride anticoagulation, coagulation PT/INR or INR testing at the point of care (POC)

Point-of-care coagulation PT/INR testing with handheld devices can help improve outcomes with more convenient and frequent measurements to keep patients within the therapeutic range of anticoagulant agents.

Feature | Point of Care Testing| May 05, 2017 | Nicholas C. Vanderslice, Ph.D., and Arnol S. Rios
Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on fi
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing| May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing| April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing| April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing| April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
warfarin dosing, genetic testing, adverse event risk, ACC.17, clinical study
News | Antiplatelet and Anticoagulation Therapies| March 27, 2017
Using genetic testing to help personalize warfarin therapy given to patients undergoing elective orthopedic surgery...
highly sensitive troponin testing
News | Cardiac Diagnostics| March 21, 2017
March 21, 2017 — A blood test for a protein called high-sensitivity troponin T, which is released into the bloodstrea
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing| March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing| January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Overlay Init